Protalix BioTherapeutics (PLX) Corporate presentation summary

Leadership and governance

• Executive team brings decades of experience in pharma, business development, and R&D, with backgrounds at major industry players.

• Board of directors includes seasoned professionals with expertise in biotech, pharma, and finance.

Commercial portfolio and partnerships

• Two approved enzyme replacement therapies: Elfabrio for Fabry disease and Elelyso for Gaucher disease, generating revenue in multiple markets.

• Strategic partnerships with Chiesi, Pfizer, and Fiocruz support commercialization and market expansion.

• Elfabrio is approved in the US, EU, and other markets, with a new every-4-weeks dosing regimen approved in the EU, reducing treatment burden.

• Elelyso is approved in 23 markets, with significant market share in Brazil.

Financial position and growth

• Reported $33.8M in Q1 2026 revenue, including a $25M milestone payment.

• Cash position of $51.1M as of March 31, 2026, with no debt or warrants and 80.5M shares outstanding.

• Three revenue streams and projected consistent medium-term growth, with significant milestone payments expected.